Attorney's Docket No. 033125

In re Patent Application of

Naohiro TAKEMOTO et al.

Application No.: 10/009,566

Filed: December 12, 2001

For:

AMINOPHENOXYACETAMIDE

DERIVATIVES AND

PHARMACEUTICAL COMPOSITION

CONTAINING THEREOF

Group Art Unit: Unassigned

Examiner: Unassigned

Confirmation No.: Unassigned

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Enclosed is an Information Disclosure Statement and accompanying form PTO-1449 for the above-identified patent application.

[X]	No additional	fee for	submission	of an	IDS is	required.

- The fee of \$180.00 (126) as set forth in 37 C.F.R. § 1.17(p) is also enclosed. []
- A certification under 37 C.F.R. § 1.97(e) is also enclosed. []
- A certification under 37 C.F.R. § 1.97(e), and the fee of \$180.00 (126) as set forth [] in 37 C.F.R. § 1.17(p) are also enclosed.
- to Deposit Account No. 02-4800 for the fee due. []
- A check in the amount of \$ is enclosed for the fee due. []

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

P.O. Box 1404 Alexandria, Virginia 22313-1404

(703) 836-6620

Date: July 26, 2002

Dawn M. Gardner

Registration No. 44,118



Attorney's Docket No. \$\overline{4025} \docket \docket

Patent #2025-002

DEC 0:3 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of	·
Naohiro TAKEMOTO et al.	
Application No.: 10/009,566) Group Art Unit: Unassigned)) Examiner: Unassigned
Filed: December 12, 2001) Confirmation No.: Unassigned
For: AMINOPHENOXYACETAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF))))

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed. Also enclosed is a copy of the International Search Report. Please note that Applicants filed an Information Disclosure Statement in connection with the above-identified application on December 12, 2001 citing three references listed on the International Search Report (WO 00/23076A, EP 0982026 A and BOUILLON et al., *Steroids: Structure, Function, and Regulation*, 1995, vol. 60, no. 6, pp. 484-490). Therefore, these three listed references are not being submitted herewith.

NON-PATENT DOCUMENTS

- McMahon et al., "Calbindin-D_{28k} buffers intracellular calcium and promotes resistance to degeneration in PC12 cells", *Molecular Brain Research*, 1998, 54:56-63.
- 2. Ng et al., "The neurotoxin MPTP increases calbindin- D_{28k} levels in mouse midbrain dopaminergic neurons", *Molecular Brain Research*, 1996, 36:329-336.

Information Disclosure Statement Application Serial No. <u>10/009,566</u> Attorney's Docket No. <u>033025-002</u> Page 2

3. Masumura et al., "Selective induction of fibroblast growth fact or receptor-1 mRNA after transient focal ischemia in the cerebral cortex of rats", *Neuroscience*

The documents are being submitted within 3 months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later, therefore under 37 C.F.R. § 1.97(b) no fee or statement is required.

Letters, 1996, 213:119-122.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Dawn M. Gardner

Registration No. 44,118

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: July 26, 2002

ATTORNEY'S DKT NO. 033025-002 10/009,566

INFORMATION DISCLOSURE

STAFFMENT BY APPLICANT

BY APPLICANT

Nachiro TAKEMOTO et al.

FILING DATE

December 12, 2001 Unassigned

JUL	2 6 2002 u			_						
E	J.	, l	U.S. PATENT DOCU	IMENTS						
Examiner Initials	U. Satent ACEMP	Cocument Kind Code (if known)	Name of Patentee or Applicant of Cited Document			Date of Publication (MM-DD-YYYY)				
		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,								
						4 1				
		 				至。并	<u> </u>			
	 	 			•	H GENTER 1800/2	}			
		1				3	"			
						7 8	त्त			
	 					8 8	O			
						136				
						9				
			REIGN PATENT DO	CUMENTS		Control of the second		- A		
F	Foreign Patent				Ω.	ata of Dublication	7	t-4'		
Examiner Initials	Number	Kind Code (if known)	Country			ate of Publication (MM-DD-YYYY)	Trans Yes	no		
		<u> </u>								
	<u> </u>									
	T	-	ATENT LITERATURI	. P						
Examiner Initials			(in CAPITAL LETTERS), al, serial, symposium, ca publisher, city and/or co	atalog, etc.), da	ate, pag	e(s), volume-issue num				
			D _{28k} buffers intracell Molecular Brain Res				to			
	Ng et al., "The neurotoxin MPTP increases calbindin-D _{28k} levels in mouse midbrain dopaminergic neurons", <i>Molecular Brain Research</i> , 1996, 36:329-336.									
			nduction of fibroblast l cortex of rats", Ne	_		_		sient		
					,					
				*						
								-		
Examiner Signature				Date Considered						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.